Study for Evaluation of Safety and Efficacy of PADN to Treat Combined Post- and Pre- Capillary Pulmonary Hypertension Associated With Chronic Heart Failure

Inclusion Criteria: Age ≥18, ≤75 years; CpcPH must be confirmed by RHC, defined as: Mean pulmonary arterial pressure (mPAP) > 20mmHg; Pulmonary capillary wedge pressure (PCWP) > 15mmHg; Pulmonary vascular resistance (PVR) > 2WU; Chronic heart failure has been diagnosed at least 3 months before screening and have been treated on the GDMT according to 2022 AHA/ACC Guidelines for Heart Failure for at least 1 month; Clinically stable HF for at least 1 month, defined as: No need of intravenous diuretics, inotropes or vasodilators, and Systolic blood pressure (SBP) ≥ 100 and < 160 mmHg, and Resting heart rate (HR) ≥ 50 bpm and <100 bpm (<110 bpm in presence of atrial fibrillation) on the day of the procedure. NYHA class II-IVa; 6MWD ≥ 100 m and ≤ 450 m; NT-proBNP > 125pg/mL (or BNP > 35pg/mL); Understand and be willing to sign informed consent and be strictly willing to follow the protocol. Exclusion Criteria: Any of the following: Hypertrophic cardiomyopathy with left ventricular (LV) outflow tract obstruction and/or mitral valvular systolic anterior motion (SAM); or Pericardial disease; or Infiltrative or inflammatory myocardial disease; or Valvular heart disease with stenosis or with severe regurgitation; or Active endocarditis; or Symptomatic carotid stenosis, or TIA or stroke within 30 days prior to randomization; or Congenital heart disease; or Having received any revascularization, including coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within 6 months prior to randomization; or anticipated to undergo coronary revascularization (CABG or PCI) within 6 months; or Artificial pacemakers, including single-chamber, dual-chamber and three-chamber pacemakers, have been implanted or are anticipated to be implanted within 6 months; or Anticipated to undergo ablation of atrial fibrillation within 6 months; or Anticipated to undergo heart valve surgery (valve replacement, valvuloplasty) within 6 months; or Listing for heart/heart-lung transplantation or anticipated to implant a ventricular assist device (VAD) Received pulmonary arterial hypertension (PAH) targeted drugs within 1 month prior to randomization; Anticipated to undergo any surgery within the next 6 months; Cardiac index (CI) measured by RHC < 1.5L/min/m2; Severe renal insufficiency (eGFR < 30mL/min/1.73m2 by MDRD formula); Severe liver insufficiency (Child-Pugh classification B-C); Platelet count < 50 × 109/L; Life expectancy < 1 year; Systemic inflammation or other disease requiring long-term use of glucocorticoids or immunosuppressants; Active infection requiring oral or intravenous antibiotics; Cannot tolerate warfarin, aspirin, clopidogrel, and any of GDMT medicines; Body mass index (BMI) > 40 kg/m²; Pregnant or lactating women, or planning to be pregnant within one year; Participation in other clinical trials within 3 months prior to signing the informed consent; Any other circumstances that investigators deemed inappropriate to participate in this trial.